Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Wall Street Analyst Weigh In

EXAS has been the topic of several recent analyst reports. Raymond James cut their price objective on shares of Exact Sciences from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Wednesday, August 3rd. Cowen dropped their price objective on shares of Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, August 3rd. Cowen reduced their target price on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a research note on Wednesday, August 3rd. BTIG Research lowered their price target on Exact Sciences from $100.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday, August 3rd. Finally, StockNews.com raised Exact Sciences from a "sell" rating to a "hold" rating in a report on Tuesday, July 26th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $70.23.

Exact Sciences Stock Performance

Exact Sciences stock traded down $0.92 during mid-day trading on Thursday, hitting $38.64. The company had a trading volume of 61,987 shares, compared to its average volume of 2,150,403. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of -9.35 and a beta of 1.32. Exact Sciences has a 12-month low of $35.34 and a 12-month high of $108.99. The company's fifty day moving average is $43.57 and its 200-day moving average is $57.38. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.70.

Insider Buying and Selling

In other news, Director Katherine S. Zanotti sold 4,608 shares of the firm's stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the sale, the director now directly owns 60,318 shares in the company, valued at approximately $2,722,754.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Katherine S. Zanotti sold 4,608 shares of the stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the transaction, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Katherine S. Zanotti sold 1,086 shares of the business's stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,701 shares of company stock valued at $251,872. Corporate insiders own 1.30% of the company's stock.